Andres Liivak

Representative matters (including prior to joining White & Case):

Biotechnology and Pharmaceutical Strategic Alliances

GSK in its $2B+ oncology development, commercialization strategic alliance with iTeos

Merck KGaA in its collaboration license arrangements for SARS-CoV-2 neutralizing antibodies with IAVI

Incyte Corporation in its collaboration to discover novel peptide-based therapeutics with Nimble Therapeutics

GSK in its synthetic lethality oncology collaboration with IDEAYA with cost- and US profit- sharing, and ex-US royalties

IAVI in its SARS-CoV-2 vaccine collaboration with Merck & Co.

GSK in its $4.2B+ global co-development, co-commercialization biologic strategic alliance collaboration with Merck KGaA

TB Alliance in its development and commercialization arrangements with Viatris for pretomanid, the first new treatment for tuberculosis in more than 40 years

Foresee Pharmaceuticals in its development, commercialization and license arrangements with partner companies for its lead development stage drug candidate

Novartis in its out-license of worldwide rights to a development stage drug with Oculis

EOFlow in its drug delivery joint venture with Zihipp focused on NASH and obesity

Incyte Corporation in its collaboration and option arrangements with Cellenkos for cord blood derived T-regulatory cells

Daiichi Sankyo Europe in its license collaboration arrangements for European rights to an oncology drug with Esperion

Verily in its strategic alliance for RA, IBS and lupus-related diseases with Gilead

Eisai in its risk sharing Alzheimer strategic alliance with Biogen for multiple development stage Alzheimer's drugs

HuyaBio in its in-licensing arrangements with several originator drug development companies based in China

Novartis/Alcon in its $1B+ option and license arrangements for single development stage asset with Lubris

Pfizer in its multi-target, multi-product, discovery and development complex option deal with Heptares

Novartis/NIBR in its development stage collaboration and license plus convertible debt deal with XOMA

Pfizer in its therapeutic area based risk sharing collaboration arrangements with OPKO

Novartis in its development, commercialization collaboration with University of Pennsylvania for CAR-T

Shionogi in its co-commercialization, co-promotion of Shionogi's Symproic® drug

Novartis/NIBR in its development, commercialization arrangements with Aduro for STING oncology immunotherapy

GSK in its "OTC-switch" in-license transaction with Merck & Co. for its MEVACOR® cardiovascular drug

Bristol-Myers Squibb in its collaboration license arrangements ImClone Systems for ERBITUX®

M&A – Biotechnology, Pharmaceutical and Medical Devices

Goldman Sachs in its acquisition of majority stake in European specialty pharma company Norgine Europe B.V.

Famy Life Sciences in its sale to Viatris together with its portfolio of development stage ophthalmology drugs

LOTTE Corporation in its $160M acquisition of a biologicals pharmaceutical manufacturing facility from Bristol-Myers Squibb

Advanz Pharma in its acquisition of the ex-US business of Intercept Pharmaceuticals

Green Cross in its acquisition of Biocentrique, a contract development & manufacturing organization (CDMO) business in New Jersey

Angelini Pharma in its $960 Million acquisition of Arvelle Therapeutics

Roche Diagnostics in its divestment and carve-out of a diagnostic subsidiary business with CardioNet

Lantheus Medical Imaging in its public company merger acquisition of Progenics

Baxter in its asset acquisition of a medical device product line business from Genzyme/Sanofi

Novartis in its multiple acquisitions of priority review vouchers

TB Alliance in the sale of its priority review voucher

Bausch Health (Valeant) in its $200M asset divestment of its Obagi® dermatology drug business

CeloNova in its sale of interventional radiology business to Boston Scientific Corporation

ViiV (JV of GSK, Pfizer, Shionogi) in its $1B+ asset acquisition of Bristol-Myers Squibb's development stage HIV drug business

Victory Pharma in its U.S. Bankruptcy Code Section 363 "Stalking Horse" bid for MiddleBrook Pharmaceuticals' anti-infective pharmaceutical product business

Life Sciences Investment Deals

Apollomics biopharmaceutical company in its US$899 million business combination with Maxpro Capital Acquisition Corp (NASDAQ: JMAC), a SPAC sponsored by Maxpro Ventures

CM Life Sciences III (NASDAQ: CMLT), a SPAC sponsored by affiliates of Casdin Capital, LLC and Corvex Management LP, in its US$3.65 billion business combination with EQRx

An affiliate of Morgan Stanley Infrastructure in its US$1.3 billion acquisition of SpecialtyCare platform of outsourced clinical OR, perfusion, intraoperative neuromonitoring and surgical services

Helix Acquisition Corp. (NASDAQ: HLXA), a SPAC, in its US$230 million business combination with MoonLake Immunotherapeutics biotechnology company

QH Oil Investments LP affiliate of Qatar Investment Authority, in its investment in the US$230 million Series B fundraising of Tessera Therapeutics

BVCF Management Ltd., China's first US dollar fund that focuses on life sciences and healthcare, in its US$15 million investment in Cellenkos biotechnology company

Biosight development stage biotech in its reverse merger transaction with Advaxis, Inc. (NASDAQ: ADXS)

Cobepa S.A. in the acquisition of MicroConstants Inc., a San Diego-based contract research organization, by BioAgilytix Labs, LLC, a portfolio company of Cobepa

Medical Device Strategic Alliances

Q-linea in its commercialization arrangements with Thermo Fischer for its antimicrobial susceptibility testing system

Biotronik in its cardiac care related medical device license and distribution arrangements with Acutus

Novartis/Alcon in its in-license arrangements with Light Matter Interaction for laser technology for use in eye surgery

Systagenix in a wound care technology acquisition deal involving anti-microbial uses of silver

Grünenthal GmbH in its device / controlled substance drug combination collaboration, license and supply arrangements

Tech and MedTech Deals

QuintoAndar in its acquisition of proptech unicorn startup Navent with operations throughout Latin America (2021 Latin America "deal of the year")

Dominus Capital, L.P. in its investment in Uptime Institute, the global digital infrastructure authority

CM Life Sciences (NASDAQ: CMLF), a SPAC sponsored by affiliates of Casdin Capital, LLC and Corvex Management LP, in its US$2 billion business combination with Mount Sinai Genomics, Inc. d/b/a Sema4 and its digital technologies

HighCape Capital Acquisition Corp. (NASDAQ: CAPA), a SPAC sponsored by HighCape Capital, a healthcare growth equity fund, in its US$1.46 billion business combination with Quantum-Si and its next generation semiconductor chip-based proteomics

Verily in its digital tech medical device related joint venture with ResMed focused on sleep apnea and breathing/sleep disorders

Novartis/Sandoz in its license and commercialization arrangements for Pear's reSET® mobile medical app

Verily in its strategic alliance arrangements for with The Broad for open-source data tools for the life sciences sector

Pfizer in its AI and digital technology collaboration with IBM on Parkinson's disease

GSK in its digital health collaboration with Propeller on respiratory inhaler medical device adherence and compliance

Carlyle Group European Technology Fund IV in its acquisition of LiveU, an Israeli-headquartered producer of portable cellular backpacks for video streaming and live broadcasting

Electric commercial vehicle company VIA Motors International, Inc. in its acquisition (in an all-stock merger valued at up to US$630 million) by Ideanomics

Operational Transactions

GSK, Celgene and Novartis in numerous companion diagnostic collaboration arrangements, including with bioMerieux, diaDexus, Phadia, Thermo Fisher, NanoString, Abbott, MolecularMD and Qiagen

Numerous manufacture and supply deals for biologics, small molecules, cell therapies and medical devices, including toll manufacturing, site transfers and tech transfers

Clinical trial, CRO and sponsored research arrangements

Software and hardware development and licensing deals

Data sharing and IT services arrangements

Evaluation, option and exclusivity arrangements

Life Sciences Licensing Contract and Royalty Disputes

Novartis in its litigation settlement and license arrangements with St. Jude relating to CAR-T

ImClone Systems in multiple patent infringement litigation settlements arrangements

GlaxoSmithKline Biologicals (GSK Vaccines) in its multi-billion dollar worldwide cross-license and settlement arrangements with Merck & Co. regarding HPV cervical cancer vaccines, GARDASIL® and CERVARIX®

GlaxoSmithKline Biologicals (GSK Vaccines) in its litigation as well as settlement arrangements with Boyce Thompson Institute regarding a licensing contract and royalty payment dispute

GlaxoSmithKline Biologicals (GSK Vaccines) in its licensing contract dispute and settlement arrangements with Biosynexus